CHMP Approves New Therapies for Immune Thrombocytopenia and Other Conditions
TL;DR Summary
The EMA's CHMP recommended approval for two new medicines, Brinsupri for bronchiectasis and Wayrilz for immune thrombocytopenia, while advising against Rezurock for graft-versus-host disease. It also approved extensions for eight existing medicines, withdrew an application for hydrocortisone in preterm infants, confirmed the suspension of Oxbryta for sickle cell disease, and introduced a new administration route for Saphnelo. The meeting's agenda and minutes are forthcoming.
- Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 October 2025 European Medicines Agency
- Europe Set to Approve New Immune Thrombocytopenia Therapy Medscape
- Press Release: Sanofi’s Wayrilz recommended for EU approval by the CHMP to treat immune thrombocytopenia Yahoo Finance
- Sanofi, Insmed among winners of CHMP recommendations (SNY) Seeking Alpha
- CHMP recommends approval of two new medicines medwatch.com
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
3 min
vs 4 min read
Condensed
90%
624 → 64 words
Want the full story? Read the original article
Read on European Medicines Agency